Theranostics Australia





Enquiry

Private Theranostics Facility in Australia

We strive to develop and provide powerful innovative therapies

Established in May 2015, we are dedicated to continuously developing and utilising targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. Contact us today to find out more.

Our knowledge of how to treat cancer is the culmination of years of research, education and application of the most innovative developments in the field. Our team of specialists, supported by advanced technologies at our facilities, works tirelessly to offer the most innovative cancer treatments on the market. This includes:

Lutetium-177 Octreotate therapy is used to treat neuroendocrine tumours (NETs) that emerge from the endocrine or nervous system such as carcinoid tumours. It aims to reduce the size of the tumour(s) and stop them from multiplying, as well as to ease the associated symptoms.

Lutetium-177 PSMA therapy is used for people with advanced prostate cancer. It is most often used when the disease has metastasised, and when other therapies are poorly tolerated or have failed. In certain patients, it can produce long-term remission.

Radium-223 therapy is used for people who have prostate cancer that has spread to the bones. The therapy damages the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether. It is also used to reduce pain that can be associated with bone cancer.

 

Iodine-131 therapy is a thyroid cancer treatment that uses radiation to treat either thyroid cancer or a hyperactive thyroid (thyrotoxicosis) by targeting the thyroid tissue.

Yttrium-90 SIRT Therapy, or Selective Internal Radiation Therapy, is a treatment for cancers and tumours located within the liver. The aim of this treatment is to reduce the size of inoperable tumours or decrease the number of lesions in the liver. It may allow for the surgical removal of tumours, once considered inoperable. It may also stabilise the disease and prolong the life of the patient.

Yttrium-90 Radiosynovectomy therapy is a treatment for painful joints caused by arthritis or other types of joint diseases, often providing relief for sufferers.

 

For modern cancer treatment and a team of specialists who care
about your wellbeing, contact us today.

Theranostics Australia has collaborative ties to

 

Testimonials

 

  • Life after Lutetium-177 PSMA therapy could not have been in more stark contrast to what had been before. There was a marked shift upward in my mood and energy which created a positive loop of activity, enjoyment and hope. I was very happy to be free and well-enough to follow through with travel plans I’d made to celebrate my wife’s 60 years. Quality of life while travelling was a 10! Lutetium-177 PSMA therapy with Theranostics Australia is a clear 10 in my experience. The medical marvel that is Lutetium was one thing; just as importantly, we finally found specialists whose advice we trusted, who were accessible, flexible and cautiously-innovative. Dr Nat Lenzo has been an outstanding source of information, advice and counsel. Theranostics Australia's unfailingly friendly and responsive patient management has been golden. I have nothing but praise for the teams and systems.

    Geoff S. (Metastatic Prostate Cancer)Lutetium-177 PSMA Therapy

    More Information

  • Thank you for your time the other day, my sister was most appreciative as was I. Your session was clear, helpful and supportive, I can’t thank you enough.

    Ms KConsultation

    More Information

New Research Hub to Expand Biomedical Imaging Boundaries

Theranostics Australia, in collaboration with other respected industry partners, will work with PhD students and early career researchers on innovative projects at an $8.5m state-of-the-art research hub to be established at The University of Queensland (UQ).

The centre will provide firsthand training to the next generation of scientists, who will expand the boundaries of biomedical imaging to improve healthcare.

The Industrial Transformation Training Centre for Innovation in Biomedical Imaging Technology (CIBIT) will prepare new scientists to work in industry and develop ‘smart’ biotechnology and biomedical imaging techniques.

The UQ Centre for Advanced Imaging (CAI) Director, Professor David Reutens, said the $8.5m research will be funded by a $4.7m Australian Research Council (ARC) grant and $3.8m in cash and in-kind contributions from industry partners.

“It will play a leading role in the future of biomedical imaging,” he said.

“Biomedical imaging has been one of the most important advances in the history of medicine.

“It allows medical professionals to determine the location, nature and extent of disease with high accuracy and sensitivity, and has become an integral part of modern health care.

“This new centre will train industry-ready scientists to lead research into faster, more accurate and more cost-effective diagnostic imaging.”

The centre’s industry driven research will work to overcome barriers in the development and application of novel diagnostics, therapeutics and theranostics for important diseases like cancer.

Sixteen PhD students and five early career researchers will work on projects with industry partners.

The centre will involve researchers from across UQ, including the Centre for Advanced Imaging (CAI), UQ Business School (UQBS), the Australian Institute for Bioengineering and Nanotechnology (AIBN), the UQ Diamantina Institute (UQDI) and the School of Mathematics and Physics (UQSMP).

Industry partners include Siemens Healthcare Pty Ltd, Clarity Pharmaceuticals Pty Ltd, Minomic International Ltd, Inter-K Peptide Therapeutics Ltd, Theranostics Australia Pty Ltd, Beijing Genomics Institute, Brisbane Veterinary Specialists Centre, Uniting Care Medical Imaging, and Red Radiology Pty Ltd.

The centre builds upon previous investments in CAI and the National Imaging Facility (NIF) from the Queensland Government and the Commonwealth Government’s contributions to the NIF through the National Collaborative Research Infrastructure Strategy (NCRIS) and the Education Investment Fund (EIF).

Original Media Release by the University of Queensland: http://bit.ly/2toXaHR

FDA Grants Accelerated Approval

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to a cancer treatment for patients whose cancers have a common biomarker, rather than the location in which the tumor originated. FDA News Release >> https://goo.gl/9Do0tD

 

Exercise Medicine to Improve Prostate Cancer Outcomes

Theranostics Australia is pleased to announce our collaboration with Edith Cowan University’s (ECU) Exercise Medicine Research Institute (EMRI) and Vario Health Clinic (VHC) regarding the use of exercise medicine to improve prostate cancer outcomes. For more information, visit >> exercisemedicine.org.au